US Regulators Mandate Eye Condition Warning for Ozempic and Wegovy

The US Food and Drug Administration (FDA) has ordered producers of glucagon-like peptide-1 (GLP-1) receptor agonist medications to include warnings about a rare eye condition that can lead to blindness.

The mandate specifically targets popular drugs like Ozempic and Wegovy, requiring their labels to detail the risk of Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION). NAION involves a sudden loss of vision, typically in one eye, caused by reduced blood flow to the optic nerve.

This directive from the US regulator follows an analysis of post-marketing reports, indicating a sufficient basis to inform patients and healthcare professionals of this potential side effect. While NAION is considered rare, its severity necessitates explicit warnings on medication packaging.

Patients currently using or considering GLP-1 drugs for diabetes management or weight loss are advised to discuss any visual changes with their medical practitioners promptly.